Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 530

1.

Clinical and morphologic predictors of outcome in older aplastic anemia patients treated with eltrombopag.

Fattizzo B, Kulasekararaj AG, Hill A, Benson-Quarm N, Griffin M, Munir T, Arnold L, Riley K, Ireland R, De Lavallade H, Potter V, Consonni D, Hillmen P, Mufti GJ, Barcellini W, Marsh JCW.

Haematologica. 2019 Mar 19. pii: haematol.2019.216374. doi: 10.3324/haematol.2019.216374. [Epub ahead of print]

2.

Reactivation of hepatitis B virus infection in patients with hematologic disorders.

Wang B, Mufti G, Agarwal K.

Haematologica. 2019 Mar;104(3):435-443. doi: 10.3324/haematol.2018.210252. Epub 2019 Feb 7. Review.

3.

Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation.

Gagelmann N, Eikema DJ, Stelljes M, Beelen D, de Wreede L, Mufti G, Knelange NS, Niederwieser D, Friis LS, Ehnninger G, Nagler A, Yakoub-Agha I, Meijer E, Ljungman P, Maertens J, Kanz L, Lopez-Corral L, Brecht A, Craddock C, Finke J, Cornelissen JJ, Bernasconi P, Chevallier P, Sierra J, Robin M, Kröger N.

Haematologica. 2019 Jan 17. pii: haematol.2018.200808. doi: 10.3324/haematol.2018.200808. [Epub ahead of print]

4.

Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill J, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK.

Biol Blood Marrow Transplant. 2018 Dec 18. pii: S1083-8791(18)30890-5. doi: 10.1016/j.bbmt.2018.12.068. [Epub ahead of print]

PMID:
30576834
5.

Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia.

Schetelig J, de Wreede LC, van Gelder M, Koster L, Finke J, Niederwieser D, Beelen D, Mufti GJ, Platzbecker U, Ganser A, Heidenreich S, Maertens J, Socié G, Brecht A, Stelljes M, Kobbe G, Volin L, Nagler A, Vitek A, Luft T, Ljungman P, Yakoub-Agha I, Robin M, Kröger N.

Leukemia. 2019 Mar;33(3):686-695. doi: 10.1038/s41375-018-0302-y. Epub 2018 Dec 20.

PMID:
30573777
6.

Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis.

Canaani J, Beohou E, Labopin M, Ghavamzadeh A, Beelen D, Hamladji RM, Niederwieser D, Volin L, Markiewicz M, Arnold R, Mufti G, Ehninger G, Socié G, Kröger N, Mohty M, Nagler A.

J Intern Med. 2019 Apr;285(4):407-418. doi: 10.1111/joim.12854. Epub 2018 Nov 16.

PMID:
30372796
7.

Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party.

Samarasinghe S, Clesham K, Iacobelli S, Sbianchi G, Knol C, Hamladji RM, Socié G, Aljurf M, Koh M, Sengeloev H, Dalle JH, Robinson S, Van Lint MT, Halkes CJM, Beelen D, Mufti GJ, Snowden J, Blaise D, de Latour RP, Marsh J, Dufour C, Risitano AM; Severe Aplastic Anaemia Working Party of the EBMT.

Am J Hematol. 2019 Jan;94(1):80-86. doi: 10.1002/ajh.25314. Epub 2018 Nov 25.

PMID:
30328134
8.

Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia.

Rice C, Eikema DJ, Marsh JCW, Knol C, Hebert K, Putter H, Peterson E, Deeg HJ, Halkes S, Pidala J, Anderlini P, Tischer J, Kroger N, McDonald A, Antin JH, Schaap NP, Hallek M, Einsele H, Mathews V, Kapoor N, Boelens JJ, Mufti GJ, Potter V, Pefault de la Tour R, Eapen M, Dufour C.

Biol Blood Marrow Transplant. 2018 Sep 5. pii: S1083-8791(18)30531-7. doi: 10.1016/j.bbmt.2018.08.029. [Epub ahead of print]

PMID:
30194027
9.

Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study.

Sengsayadeth S, Gatwood KS, Boumendil A, Labopin M, Finke J, Ganser A, Stelljes M, Ehninger G, Beelen D, Niederwieser D, Blaise D, Dreger P, Mufti G, Chevallier P, Mailhol A, Gilleece MH, Gorin N, Esteve J, Ciceri F, Baron F, Schmid C, Giebel S, Mohty M, Savani BN, Nagler A.

Blood Adv. 2018 Aug 28;2(16):2127-2135. doi: 10.1182/bloodadvances.2018019976.

10.

Posterior Reversible Encephalopathy Syndrome after Augmentation Cystoplasty in a Child with Neurogenic Bladder.

Magray MA, Mufti GN, Bhat NA, Baba AA, Buch MH, Hasan FU, Banday SB.

J Indian Assoc Pediatr Surg. 2018 Jul-Sep;23(3):158-160. doi: 10.4103/jiaps.JIAPS_204_17.

11.

Somatic Mutations in Aplastic Anemia.

Mufti GJ, Marsh JCW.

Hematol Oncol Clin North Am. 2018 Aug;32(4):595-607. doi: 10.1016/j.hoc.2018.03.002. Epub 2018 Jun 5. Review.

PMID:
30047413
12.

Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation.

Chitre S, Stölzel F, Cuthill K, Streetly M, Graham C, Dill C, Mohamedali A, Smith A, Schetelig J, Altmann H, Bornhäuser M, Mufti GJ.

Leukemia. 2018 Sep;32(9):2020-2024. doi: 10.1038/s41375-018-0208-8. Epub 2018 Jul 19. No abstract available.

PMID:
30026569
13.

Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Heinicke T, Labopin M, Schmid C, Polge E, Socié G, Blaise D, Mufti GJ, Huynh A, Brecht A, Ledoux MP, Cahn JY, Milpied N, Scheid C, Hicheri Y, Mohty M, Savani BN, Nagler A.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2224-2232. doi: 10.1016/j.bbmt.2018.07.007. Epub 2018 Aug 7.

PMID:
30009981
14.

Diagnostic algorithm for lower-risk myelodysplastic syndromes.

Mufti GJ, McLornan DP, van de Loosdrecht AA, Germing U, Hasserjian RP.

Leukemia. 2018 Aug;32(8):1679-1696. doi: 10.1038/s41375-018-0173-2. Epub 2018 Jun 26. Review.

PMID:
29946191
15.

Alemtuzumab vs anti-thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning.

Robin M, Raj K, Chevret S, Gauthier J, de Lavallade H, Michonneau D, McLornan D, Peffault de Latour R, Potter V, Kulasekararaj A, Sicre de Fontbrune F, Pagliuca A, Yakoub-Agha I, Socié G, Mufti GJ.

Eur J Haematol. 2018 Oct;101(4):466-474. doi: 10.1111/ejh.13085.

PMID:
29714032
16.

Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study.

Sengsayadeth S, Labopin M, Boumendil A, Finke J, Ganser A, Stelljes M, Ehninger G, Beelen D, Niederwieser D, Blaise D, Dreger P, Mufti G, Chevallier P, Mailhol A, Gatwood KS, Gorin N, Esteve J, Ciceri F, Baron F, Schmid C, Giebel S, Mohty M, Savani BN, Nagler A.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1406-1414. doi: 10.1016/j.bbmt.2018.04.008. Epub 2018 Apr 17.

17.

miR-181c-BRK1 axis plays a key role in actin cytoskeleton-dependent T cell function.

Lim SP, Ioannou N, Ramsay AG, Darling D, Gäken J, Mufti GJ.

J Leukoc Biol. 2018 May;103(5):855-866. doi: 10.1002/JLB.1A0817-325RR. Epub 2018 Apr 14.

PMID:
29656550
18.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526c.

PMID:
29634689
19.

Anti-type M phospholipase A2 receptor antibody-positive membranous nephropathy as a part of multi-system autoimmune syndrome post-allogeneic stem cell transplantation.

Tedjaseputra A, McLornan D, McCormick J, Raj K, de Lavallade H, Potter V, Kenyon M, Pagliuca A, Marsh J, Mufti G.

Intern Med J. 2018 Apr;48(4):481-483. doi: 10.1111/imj.13762. No abstract available.

PMID:
29623981
20.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. Erratum in: Nat Med. 2018 Apr 10;24(4):526.

21.

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission.

Saraceni F, Labopin M, Hamladji RM, Mufti G, Socié G, Shimoni A, Delage J, Deconinck E, Chevallier P, Blaise D, Sanz J, Huynh A, Forcade E, Savani BN, Mohty M, Nagler A; Acute Leukemia Working Party of the European society for Blood and Marrow Transplantation (EBMT).

Oncotarget. 2017 Dec 15;9(3):3379-3393. doi: 10.18632/oncotarget.23273. eCollection 2018 Jan 9.

22.

Heterozygous RTEL1 variants in bone marrow failure and myeloid neoplasms.

Marsh JCW, Gutierrez-Rodrigues F, Cooper J, Jiang J, Gandhi S, Kajigaya S, Feng X, Ibanez MDPF, Donaires FS, Lopes da Silva JP, Li Z, Das S, Ibanez M, Smith AE, Lea N, Best S, Ireland R, Kulasekararaj AG, McLornan DP, Pagliuca A, Callebaut I, Young NS, Calado RT, Townsley DM, Mufti GJ.

Blood Adv. 2018 Jan 4;2(1):36-48. doi: 10.1182/bloodadvances.2017008110. eCollection 2018 Jan 9.

23.

Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation.

Devillier R, Labopin M, Chevallier P, Ledoux MP, Socié G, Huynh A, Bourhis JH, Cahn JY, Roth-Guepin G, Mufti G, Desmier D, Michallet M, Fegueux N, Ciceri F, Baron F, Blaise D, Nagler A, Mohty M.

Bone Marrow Transplant. 2018 Apr;53(4):431-437. doi: 10.1038/s41409-017-0043-y. Epub 2018 Jan 12.

24.

Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation.

Shimoni A, Labopin M, Savani B, Hamladji RM, Beelen D, Mufti G, Socié G, Delage J, Blaise D, Chevallier P, Forcade E, Deconinck E, Mohty M, Nagler A.

Biol Blood Marrow Transplant. 2018 Apr;24(4):751-757. doi: 10.1016/j.bbmt.2017.12.776. Epub 2017 Dec 13.

PMID:
29247780
25.

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion.

Garderet L, Ziagkos D, van Biezen A, Iacobelli S, Finke J, Maertens J, Volin L, Ljungman P, Chevallier P, Passweg J, Schaap N, Beelen D, Nagler A, Blaise D, Poiré X, Yakoub-Agha I, Lenhoff S, Craddock C, Schots R, Rambaldi A, Sanz J, Jindra P, Mufti GJ, Robin M, Kröger N.

Biol Blood Marrow Transplant. 2018 Mar;24(3):507-513. doi: 10.1016/j.bbmt.2017.11.017. Epub 2017 Nov 28.

26.

Shortened telomeres in essential thrombocythemia: clinicopathological and treatment correlations.

Alimam S, McLornan DP, Jiang J, Radia D, Mufti GJ, Harrison CN.

Haematologica. 2018 Jun;103(6):e234-e236. doi: 10.3324/haematol.2017.180851. Epub 2017 Nov 30. No abstract available.

27.

Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation.

Schmid C, de Wreede LC, van Biezen A, Finke J, Ehninger G, Ganser A, Volin L, Niederwieser D, Beelen D, Alessandrino P, Kanz L, Schleuning M, Passweg J, Veelken H, Maertens J, Cornelissen JJ, Blaise D, Gramatzki M, Milpied N, Yakoub-Agha I, Mufti G, Rovira M, Arnold R, de Witte T, Robin M, Kröger N.

Haematologica. 2018 Feb;103(2):237-245. doi: 10.3324/haematol.2017.168716. Epub 2017 Nov 3.

28.

Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party.

Scheid C, de Wreede L, van Biezen A, Koenecke C, Göhring G, Volin L, Maertens J, Finke J, Passweg J, Beelen D, Cornelissen JJ, Itälä-Remes M, Chevallier P, Russell N, Petersen E, Milpied N, Richard Espiga C, Peniket A, Sierra J, Mufti G, Crawley C, Veelken JH, Ljungman P, Cahn JY, Alessandrino EP, de Witte T, Robin M, Kröger N.

Bone Marrow Transplant. 2017 Nov;52(11):1519-1525. doi: 10.1038/bmt.2017.171. Epub 2017 Sep 11.

29.

Buck's fascia repair with glanuloplasty in hypospadias surgery: A simple approach with excellent outcome.

Baba AA, Wani SA, Bhat NA, Mufti GN, Lone TN, Nazir S.

J Pediatr Urol. 2017 Dec;13(6):633.e1-633.e5. doi: 10.1016/j.jpurol.2017.06.015. Epub 2017 Jul 16.

PMID:
28789936
30.

Women Administered Standard Dose Imatinib for Chronic Myeloid Leukemia Have Higher Dose-Adjusted Plasma Imatinib and Norimatinib Concentrations Than Men.

Belsey SL, Ireland R, Lang K, Kizilors A, Ho A, Mufti GJ, Bisquera A, De Lavallade H, Flanagan RJ.

Ther Drug Monit. 2017 Oct;39(5):499-504. doi: 10.1097/FTD.0000000000000440.

PMID:
28767619
31.

Pre-symptomatic (Baseline) computed tomography predicts invasive pulmonary aspergillosis in high-risk adult haemato-oncology patients.

Ceesay MM, Desai SR, Cleverley J, Berry L, Smith M, Wade J, Mufti GJ, Pagliuca A.

Br J Haematol. 2018 Sep;182(5):723-727. doi: 10.1111/bjh.14858. Epub 2017 Jul 24. No abstract available.

PMID:
28737208
32.

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes.

Unnikrishnan A, Papaemmanuil E, Beck D, Deshpande NP, Verma A, Kumari A, Woll PS, Richards LA, Knezevic K, Chandrakanthan V, Thoms JAI, Tursky ML, Huang Y, Ali Z, Olivier J, Galbraith S, Kulasekararaj AG, Tobiasson M, Karimi M, Pellagatti A, Wilson SR, Lindeman R, Young B, Ramakrishna R, Arthur C, Stark R, Crispin P, Curnow J, Warburton P, Roncolato F, Boultwood J, Lynch K, Jacobsen SEW, Mufti GJ, Hellstrom-Lindberg E, Wilkins MR, MacKenzie KL, Wong JWH, Campbell PJ, Pimanda JE.

Cell Rep. 2017 Jul 18;20(3):572-585. doi: 10.1016/j.celrep.2017.06.067.

33.
34.

Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT.

Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N.

Bone Marrow Transplant. 2017 Jul;52(7):1081. doi: 10.1038/bmt.2017.86.

PMID:
28677682
35.

Preclinical modeling of myelodysplastic syndromes.

Rouault-Pierre K, Mian SA, Goulard M, Abarrategi A, Di Tulio A, Smith AE, Mohamedali A, Best S, Nloga AM, Kulasekararaj AG, Ades L, Chomienne C, Fenaux P, Dosquet C, Mufti GJ, Bonnet D.

Leukemia. 2017 Dec;31(12):2702-2708. doi: 10.1038/leu.2017.172. Epub 2017 Jun 2.

36.

British Committee for Standards in Haematology guidelines for aplastic anemia: Single centre retrospective review finds no compelling evidence for the recommended higher platelet count threshold of 20 × 109 /L - RESPONSE to Yan et al.

Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hillmen P, Ireland R, Kulasekararaj A, Mufti G, Snowden JA, Samarasinghe S, Wood A, Marsh JCW; British Society for Standards in Haematology AA Guidelines Committee.

Br J Haematol. 2018 Jul;182(2):286-287. doi: 10.1111/bjh.14766. Epub 2017 May 23. No abstract available.

PMID:
28542907
37.

Post ventriculoperitoneal shunt abdominal pseudocyst: Challenges posed in management.

Hamid R, Baba AA, Bhat NA, Mufti G, Mir YA, Sajad W.

Asian J Neurosurg. 2017 Jan-Mar;12(1):13-16. doi: 10.4103/1793-5482.145539.

38.

Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes.

Martino R, Henseler A, van Lint M, Schaap N, Finke J, Beelen D, Vigouroux S, Alessandrino EP, Mufti GJ, Veelken JH, Bruno B, Yakoub-Agha I, Volin L, Maertens J, Or R, Leblond V, Rovira M, Kalhs P, Alvarez AF, Vitek A, Sierra J, Wagner E, Robin M, de Witte T, Kröger N.

Bone Marrow Transplant. 2017 Aug;52(8):1107-1112. doi: 10.1038/bmt.2017.19. Epub 2017 Mar 20.

PMID:
28319072
39.

FLT3 and JAK2 Mutations in Acute Myeloid Leukemia Promote Interchromosomal Homologous Recombination and the Potential for Copy Neutral Loss of Heterozygosity.

Gaymes TJ, Mohamedali A, Eiliazadeh AL, Darling D, Mufti GJ.

Cancer Res. 2017 Apr 1;77(7):1697-1708. doi: 10.1158/0008-5472.CAN-16-1678. Epub 2017 Jan 20.

40.

Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.

de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti GJ, Fenaux P, Sanz G, Martino R, Alessandrino EP, Onida F, Symeonidis A, Passweg J, Kobbe G, Ganser A, Platzbecker U, Finke J, van Gelder M, van de Loosdrecht AA, Ljungman P, Stauder R, Volin L, Deeg HJ, Cutler C, Saber W, Champlin R, Giralt S, Anasetti C, Kröger N.

Blood. 2017 Mar 30;129(13):1753-1762. doi: 10.1182/blood-2016-06-724500. Epub 2017 Jan 17. Review.

41.

Versatile humanized niche model enables study of normal and malignant human hematopoiesis.

Abarrategi A, Foster K, Hamilton A, Mian SA, Passaro D, Gribben J, Mufti G, Bonnet D.

J Clin Invest. 2017 Feb 1;127(2):543-548. doi: 10.1172/JCI89364. Epub 2017 Jan 9.

42.

Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT.

Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N.

Bone Marrow Transplant. 2017 Feb;52(2):209-215. doi: 10.1038/bmt.2016.266. Epub 2016 Nov 7. Erratum in: Bone Marrow Transplant. 2017 Jul;52(7):1081.

PMID:
27819688
43.

Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells.

Grimaldi F, Potter V, Perez-Abellan P, Veluchamy JP, Atif M, Grain R, Sen M, Best S, Lea N, Rice C, Pagliuca A, Mufti GJ, Marsh JCW, Barber LD.

Biol Blood Marrow Transplant. 2017 Feb;23(2):293-299. doi: 10.1016/j.bbmt.2016.11.003. Epub 2016 Nov 2.

44.

Myelodysplastic syndrome can propagate from the multipotent progenitor compartment.

Rouault-Pierre K, Smith AE, Mian SA, Pizzitola I, Kulasekararaj AG, Mufti GJ, Bonnet D.

Haematologica. 2017 Jan;102(1):e7-e10. doi: 10.3324/haematol.2016.152520. Epub 2016 Oct 6. No abstract available.

45.

Spontaneous myonecrosis in chronic myeloid leukaemia.

Renshaw H, Gandhi S, Shah A, Ireland R, Marsh JC, Mufti GJ.

Br J Haematol. 2016 Oct;175(2):190. doi: 10.1111/bjh.14278. Epub 2016 Aug 12. No abstract available.

PMID:
27514928
46.

RPL27A is a target of miR-595 and may contribute to the myelodysplastic phenotype through ribosomal dysgenesis.

Alkhatabi HA, McLornan DP, Kulasekararaj AG, Malik F, Seidl T, Darling D, Gaken J, Mufti GJ.

Oncotarget. 2016 Jul 26;7(30):47875-47890. doi: 10.18632/oncotarget.10293.

47.

Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.

Santini V, Almeida A, Giagounidis A, Gröpper S, Jonasova A, Vey N, Mufti GJ, Buckstein R, Mittelman M, Platzbecker U, Shpilberg O, Ram R, Del Cañizo C, Gattermann N, Ozawa K, Risueño A, MacBeth KJ, Zhong J, Séguy F, Hoenekopp A, Beach CL, Fenaux P.

J Clin Oncol. 2016 Sep 1;34(25):2988-96. doi: 10.1200/JCO.2015.66.0118. Epub 2016 Jun 27.

PMID:
27354480
48.

Baseline cytokine profiling identifies novel risk factors for invasive fungal disease among haematology patients undergoing intensive chemotherapy or haematopoietic stem cell transplantation.

Ceesay MM, Kordasti S, Rufaie E, Lea N, Smith M, Wade J, Douiri A, Mufti GJ, Pagliuca A.

J Infect. 2016 Sep;73(3):280-8. doi: 10.1016/j.jinf.2016.04.040. Epub 2016 Jun 22.

PMID:
27343564
49.

Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment.

Kordasti S, Costantini B, Seidl T, Perez Abellan P, Martinez Llordella M, McLornan D, Diggins KE, Kulasekararaj A, Benfatto C, Feng X, Smith A, Mian SA, Melchiotti R, de Rinaldis E, Ellis R, Petrov N, Povoleri GA, Chung SS, Thomas NS, Farzaneh F, Irish JM, Heck S, Young NS, Marsh JC, Mufti GJ.

Blood. 2016 Sep 1;128(9):1193-205. doi: 10.1182/blood-2016-03-703702. Epub 2016 Jun 8.

50.

Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research.

Potter VT, Iacobelli S, van Biezen A, Maertens J, Bourhis JH, Passweg JR, Yakhoub-Agha I, Tabrizi R, Bay JO, Chevallier P, Chalandon Y, Huynh A, Cahn JY, Ljungman P, Craddock C, Lenhoff S, Russell NH, Fegueux N, Socié G, Bruno B, Meijer E, Mufti GJ, de Witte T, Robin M, Kröger N.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1615-1620. doi: 10.1016/j.bbmt.2016.05.026. Epub 2016 Jun 3.

Supplemental Content

Support Center